Longeveron LLC

Longeveron expects to report top-line data from its ELPIS II trial in Hypoplastic Left Heart Syndrome in mid-September, while its cash runway extends into the fourth quarter of 2026. CEO Stephen Willard said the company is prioritizing the ELPIS II readout as its most important near-term catalyst and sees no blockers to a Biologics License Application if the data are positive, with a priority review voucher available. CFO Marie Washburn reported revenues of $0.3 million for the three months ended June 30, 2026, a net loss of $6.1 million, and cash and cash equivalents of $10.1 million as of June 30, 2026. The company also highlighted its selection as a finalist for the XPRIZE HealthSpan competition, where top Milestone 2 award-winning teams each receive $1 million, and said it plans to seek partnerships for commercialization.

Longeveron announced that its cellular therapy laromestrocel reduced neuroinflammation in patients with mild Alzheimer’s disease, according to new post-hoc analysis of Phase 2a trial data presented at the 2026 Alzheimer’s Association International Conference. The poster presentation showed that free water, an MRI marker of brain inflammation, rose in the placebo group over 39 weeks but was numerically reduced in all laromestrocel treatment groups, with the anti-inflammatory effect most prominent in the hippocampus, temporal lobe, and other Alzheimer’s-associated regions. The reduction in free water correlated with increased brain volume and improved cognitive and quality of life scores. Blood biomarker analysis indicated a reduction in neurogranin, a marker of neuronal degradation, and an increase in the anti-inflammatory cytokine IL-13 in treated patients. Longeveron has received U.S. FDA Regenerative Medicine Advanced Therapy designation for its Alzheimer’s program and has aligned on a Phase 3 study design.